Real-world Secukinumab Outcomes in Canadian HS Patients

Recruiting now

Conditions studied: Hidradenitis Suppurativa

In brief

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Key facts

Study ID

NCT07282015

Run by

Novartis Pharmaceuticals

People needed

142

Starts

2025-12-12

Expected to finish

2028-02-11

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
• Adult patients at the time of informed consent signature.
• Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
• Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
• Patients who can understand written and spoken Canadian English or French.

You may not qualify if…

• Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
• Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
• Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit).

Where it is running

• Novartis Investigative Site — Calgary, Alberta, Canada (enrolling)
• Novartis Investigative Site — Calgary, Alberta, Canada (enrolling)
• Novartis Investigative Site — Winnipeg, Manitoba, Canada (enrolling)
• Novartis Investigative Site — Fredericton, New Brunswick, Canada (enrolling)
• Novartis Investigative Site — St. John's, Newfoundland and Labrador, Canada (enrolling)
• Novartis Investigative Site — Cobourg, Ontario, Canada (enrolling)
• Novartis Investigative Site — Hamilton, Ontario, Canada (enrolling)
• Novartis Investigative Site — London, Ontario, Canada (enrolling)
• Novartis Investigative Site — Markham, Ontario, Canada (enrolling)
• Novartis Investigative Site — Mississauga, Ontario, Canada (enrolling)
• Novartis Investigative Site — Richmond Hill, Ontario, Canada (enrolling)
• Novartis Investigative Site — Toronto, Ontario, Canada (enrolling)
• Novartis Investigative Site — Saint-Jérôme, Quebec, Canada (enrolling)
• Novartis Investigative Site — Sherbrooke, Quebec, Canada (enrolling)
• Novartis Investigative Site — Saskatoon, Saskatchewan, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.